AbbVie’s Epkinly (epcoritamab-bysp) Receives the US FDA’s Accelerated Approval to Treat R/R Follicular Lymphoma
Shots:
- The accelerated approval was based on P-I/II (EPCORE NHL-1) study of Epkinly (SC) in adults (n=127) with r/r or progressive CD20+ mature B-NHL incl. FL post ≥2L of systemic therapy. Full approval depends on confirmatory studies
- Trial depicted an ORR of 82%, CR rate of 60% & PR rate of 22% with >50% of responders sustaining their responses to the treatment at 14.8mos. of median follow-up
- Epcoritamab, an IgG1-bispecific Ab developed using Genmab's DuoBody technology, activates T-cell-induced CD20+ cell destruction by binding with CD3 & CD20 on T & B cells, respectively. Additionally, both companies will co-develop & commercialize it in the US & Japan, whereas AbbVie will commercialize it in ROW solely
Ref: AbbVie | Image: AbbVie
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
